Crispr Therapeutics AG (CRSP) AI Stock Analysis

• Market Cap: $2.86B
• Dividend Yield: N/A
• Average Volume (3M): 2.18M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.99
• Revenue Growth: -86.13%
• EPS Growth: -67.29%
• Country: US
• Employees: 393
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): -1.58
• Shares Outstanding: 86,363,160
• 10 Day Avg. Volume: 1,642,363
• 30 Day Avg. Volume: 2,176,117
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.59
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 45.12
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $70.05
• Price Target Upside: 104.53% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 20

Crispr Therapeutics AG's stock score reflects significant financial challenges with negative income and cash flow metrics, despite a strong balance sheet. Technical indicators show mixed signals with a potential downward trend, and valuation metrics suggest the stock may be overvalued. The absence of earnings call and corporate events data means these factors did not influence the score.

Positive Factors

Clinical Trials

Initial data for CTX310 demonstrated up to 75% reduction in ANGPTL3 from baseline, which correlated with reductions in triglycerides and LDL, showing proof-of-concept that CRISPR can accomplish in vivo gene editing safely.

Product Launch

Vertex has activated more than 65 authorized treatment centers globally and more than 90 patients have initiated cell collection, indicating progress in the commercial launch of Casgevy in sickle cell disease and transfusion-dependent β-thalassemia.

Revenue Growth

CASGEVY revenues totaled $14M in 1Q25—this represents a 75% increase from $8M in 4Q24.

Negative Factors

Financial Performance

CRSP reported a net loss per share of ($1.58) compared to the consensus of ($1.23).

Market Challenges

Uptake has been slow due to the intense commitment of the myeloablation conditioning regimen and the permanent nature and novelty of gene editing.

Crispr Therapeutics AG Business Overview & Revenue Model

Company Description

Crispr Therapeutics AG (CRSP) is a leading biotechnology company focused on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 platform. The company operates primarily in the healthcare sector, with a core focus on gene editing technologies. Crispr Therapeutics is dedicated to creating therapies for serious diseases such as hemoglobinopathies, oncology, regenerative medicine, and rare diseases.

How the Company Makes Money

Crispr Therapeutics AG generates revenue through a combination of collaboration agreements, milestone payments, and potential royalties from its partnerships with other biotechnology and pharmaceutical companies. Key revenue streams include collaborations with industry leaders like Vertex Pharmaceuticals, with whom it co-develops treatments for genetic diseases. The company also receives research funding and upfront payments from these collaborations, contributing to its earnings. Additionally, Crispr Therapeutics may generate future revenue from the commercialization of its proprietary therapies once they receive regulatory approval and are brought to market.

Crispr Therapeutics AG Financial Statement Overview

Summary

Crispr Therapeutics AG faces significant financial challenges, particularly in revenue generation and profitability. The income statement reveals a drastic revenue decline and negative profit margins, indicating operational struggles. However, the balance sheet is strong with substantial equity and cash reserves, providing some stability. Cash flow issues persist, with negative free cash flow and reliance on external financing.

Income Statement

Crispr Therapeutics AG has shown significant volatility in revenue and profit margins. The most recent annual report indicates a drastic revenue decline compared to previous years, with a sharp drop from 2021 to 2024. Gross and net profit margins have turned negative, highlighting operational challenges and high expenses relative to revenue. The TTM data shows a negative EBIT and EBITDA margin, indicating operational inefficiencies and ongoing financial struggles.

Balance Sheet

The company maintains a strong equity position with a high equity ratio, suggesting stability in its capital structure. While the debt-to-equity ratio is relatively low, indicating manageable leverage, the stockholders' equity has slightly declined over the years. The balance sheet reflects a solid cash position, which is crucial for a biotech firm investing in R&D, despite the negative net income.

Cash Flow

Crispr Therapeutics AG exhibits a negative free cash flow trend, with operating cash flows consistently negative over recent years. This indicates potential liquidity challenges. The free cash flow to net income ratio is also negative, underscoring ongoing cash management issues. The cash flow from financing has been positive, which may provide temporary relief but signifies reliance on external funding.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
35.00M	371.21M	436.00K	913.08M	543.00K
	Gross Profit
37.31M	240.96M	-109.81M	895.13M	-268.86M
	EBIT
-466.57M	-222.54M	-673.16M	373.53M	-354.44M
	EBITDA
-466.57M	-202.70M	-648.99M	391.48M	-345.25M
	Net Income Common Stockholders
-366.25M	-153.61M	-650.17M	377.66M	-348.87M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.90B	1.69B	1.82B	2.38B	1.69B
	Total Assets
2.24B	2.23B	2.24B	2.75B	1.83B
	Total Debt
223.69M	238.63M	244.02M	225.03M	61.43M
	Net Debt
-74.56M	-150.84M	32.14M	-698.00M	-1.11B
	Total Liabilities
309.95M	346.77M	367.58M	352.42M	163.73M
	Stockholders Equity
1.93B	1.88B	1.88B	2.40B	1.66B
Cash Flow		Free Cash Flow
-144.68M	-272.35M	-532.93M	457.27M	-256.72M
	Operating Cash Flow
-142.77M	-260.38M	-495.74M	538.97M	-238.37M
	Investing Cash Flow
-280.48M	374.65M	-258.65M	-1.04B	-541.17M
	Financing Cash Flow
331.98M	62.66M	38.59M	250.94M	1.02B

Crispr Therapeutics AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 34.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRSP, the sentiment is Negative. The current price of 34.25 is below the 20-day moving average (MA) of 37.48, below the 50-day MA of 38.99, and below the 200-day MA of 44.87, indicating a bearish trend. The MACD of -0.70 indicates Positive momentum. The RSI at 39.65 is Neutral, neither overbought nor oversold. The STOCH value of 18.20 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRSP.

Crispr Therapeutics AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HRMY	76 Outperform	$1.84B	12.22	24.71%	―	20.62%	14.08%
Sector *	52 Neutral	$5.23B	3.70	-41.86%	2.84%	16.58%	-0.16%
CRSP	50 Neutral	$2.86B	―	-19.71%	―	-86.13%	-67.29%
ARQT	48 Neutral	$1.71B	―	-70.58%	―	100.03%	64.22%
VERV	48 Neutral	$388.66M	―	-36.36%	―	174.98%	25.06%
BEAM	40 Underperform	$2.04B	―	-38.04%	―	-82.38%	-164.76%
NTLA	39 Underperform	$750.97M	―	-54.00%	―	59.55%	3.09%

Crispr Therapeutics AG Corporate Events

CRISPR Therapeutics COO Julianne Bruno Resigns

On March 24, 2025, Julianne Bruno, the Chief Operating Officer of CRISPR Therapeutics, announced her resignation effective April 11, 2025, to pursue external opportunities. Her departure is not due to any disagreement with the company. Bruno has been a key figure in advancing the company’s hematology and oncology programs and other initiatives. Her resignation marks a significant transition for CRISPR Therapeutics, which continues to strengthen its position in the biopharmaceutical industry through strategic partnerships and innovative gene-editing solutions.